Literature DB >> 17162426

Cardiovascular risk factors in the Mexican population.

Guillermo Garcia-Garcia1, Raymundo Aviles-Gomez, Victor H Luquin-Arellano, Ruben Padilla-Ochoa, Lourdes Lepe-Murillo, Margarita Ibarra-Hernandez, Gregorio Briseño-Renteria.   

Abstract

Chronic degenerative disorders have become a major health problem in Mexico. Cardiovascular diseases represent the first cause of death in our country. Diabetes mellitus (DM) has emerged as the main health problem in Mexico. Its prevalence doubled from < 3% in the 1960s to 6% in the 1980s. Between 1993 and 2000, diabetes mellitus increased from 6.7% to 8.2%, a 22% growth over a seven-year period. In 1995, the cost of the treatment of DM represented 15.48% of the health budget and 0.79% of the GDP. The prevalence of hypertension (HTN) increased from 10% in 1933 to 20% in 1990 and from 23.8% to 30.7% between 1993 and 2000. The expenditures from HTN in 1999 corresponded to 13.9% of the health budget, and 0.71% of GDP. Dyslipidemias are very common. Close to 40% of the population has levels of HDL cholesterol < 35 mg/dL, 24.3% has fasting triglycerides > 200 mg/dL, and 10% has hypercholesterolemia. The prevalence of obesity increased from 21.4% in 1993, to 23.7% in the year 2000. Eight percent of the population has a glomerular filtration rate < 60 mL/min, and 9.1% has proteinuria. Twenty-four percent uses tobacco regularly, and 13% had the habit in the past. Smoking is more frequent among diabetics (34%).In conclusion, cardiovascular risks factors are highly common among the Mexican population and increasing at alarming rates. Preventive programs targeted to decrease their prevalence are urgently needed in Mexico and should become a national priority.

Entities:  

Mesh:

Year:  2006        PMID: 17162426     DOI: 10.1080/08860220600936096

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  Effect of maternal birthplace on gestational diabetes prevalence in Colorado Hispanics.

Authors:  Patricia A Braun; Amy G Huebschmann; Christina A Kim; Dennis C Lezotte; Alyson Shupe; Dana Dabelea
Journal:  J Immigr Minor Health       Date:  2011-06

2.  Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians.

Authors:  Ellen T Chang; Juan Yang; Theresa Alfaro-Velcamp; Samuel K S So; Sally L Glaser; Scarlett Lin Gomez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-12       Impact factor: 4.254

Review 3.  Erectile dysfunction therapy in countries where implant is economically not feasible.

Authors:  Adrián M Garza-Gangemi; Mariano Sotomayor-de Zavaleta
Journal:  Transl Androl Urol       Date:  2017-04

4.  Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients.

Authors:  Joel Rodríguez-Saldaña; Francisco Padilla-Padilla; Ernesto G Cardona-Muñoz; Yulia Romero-Antonio; María Marcela Arguedas-Núñez; José G Sander-Padilla; Alberto Martínez-Muñoz; Laura A Lugo-Sánchez; Ileana C Rodríguez-Vazquez; Jorge González-Canudas
Journal:  Cardiol Res Pract       Date:  2022-09-10       Impact factor: 1.990

5.  Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report.

Authors:  Patricia V Torres-Duran; Aldo Ferreira-Hermosillo; Marco A Juarez-Oropeza
Journal:  Lipids Health Dis       Date:  2007-11-26       Impact factor: 3.876

6.  Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management.

Authors:  Maria Isabel Esparza; Xilong Li; Beverley Adams-Huet; Chandna Vasandani; Amy Vora; Sandeep R Das; Abhimanyu Garg; Zahid Ahmad
Journal:  J Endocr Soc       Date:  2019-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.